Zobrazeno 1 - 10
of 197
pro vyhledávání: '"A. F., Farago"'
Autor:
Aaron S. Mansfield, David S. Hong, Christine L. Hann, Anna F. Farago, Himisha Beltran, Saiama N. Waqar, Andrew E. Hendifar, Lowell B. Anthony, Matthew H. Taylor, Alan H. Bryce, Scott T. Tagawa, Karl Lewis, Jiaxin Niu, Christine H. Chung, James M. Cleary, Michael Rossi, Carrianne Ludwig, Ricardo Valenzuela, Yan Luo, Rahul Aggarwal
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-7 (2021)
Abstract Delta-like protein 3 (DLL3) is highly expressed in solid tumors, including neuroendocrine carcinomas/neuroendocrine tumors (NEC/NET). Rovalpituzumab tesirine (Rova-T) is a DLL3-targeting antibody-drug conjugate. Patients with NECs and other
Externí odkaz:
https://doaj.org/article/41cea5032a0d44ac9ceef9a9bed44b7a
Autor:
Biagio Ricciuti, MD, Abdul Rafeh Naqash, MD, Jarushka Naidoo, MD, Kartik Sehgal, MD, Adam Miller, MD, Kenneth Kehl, MD, MPH, Deepti Venkatraman, MPH, Jacob Sands, MD, Giuseppe Lamberti, MD, Gonzalo Recondo, MD, PhD, Jiajia Zhang, MD, Shravanti Macherla, MD, Sameer Baig, MD, Paul Walker, MD, Deepa Rangachari, MD, Justin F. Gainor, MD, Daniel B. Costa, MD, Naiyer Rizvi, MD, Lynette M. Sholl, MD, Mizuki Nishino, MD, MPH, Brian Henick, MD, Anna F. Farago, MD, PhD, Mark M. Awad, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 4, Pp 100074- (2020)
Introduction: The development of immune-related adverse events (irAEs) has been associated with improved efficacy of immune checkpoint inhibitors in patients with urothelial cancer, melanoma, and NSCLC. Whether this association exists in patients wit
Externí odkaz:
https://doaj.org/article/44c33d5b25fc49e0a525d0f78bde07d6
Autor:
David P. Kodack, Anna F. Farago, Anahita Dastur, Matthew A. Held, Leila Dardaei, Luc Friboulet, Friedrich von Flotow, Leah J. Damon, Dana Lee, Melissa Parks, Richard Dicecca, Max Greenberg, Krystina E. Kattermann, Amanda K. Riley, Florian J. Fintelmann, Coleen Rizzo, Zofia Piotrowska, Alice T. Shaw, Justin F. Gainor, Lecia V. Sequist, Matthew J. Niederst, Jeffrey A. Engelman, Cyril H. Benes
Publikováno v:
Cell Reports, Vol 21, Iss 11, Pp 3298-3309 (2017)
Personalized cancer therapy is based on a patient’s tumor lineage, histopathology, expression analyses, and/or tumor DNA or RNA analysis. Here, we aim to develop an in vitro functional assay of a patient’s living cancer cells that could complemen
Externí odkaz:
https://doaj.org/article/016db17b42214179a6109aad4764e0a1
Autor:
Christopher Alvarez-Breckenridge, Julie J. Miller, Naema Nayyar, Corey M. Gill, Andrew Kaneb, Megan D’Andrea, Long P. Le, Jesse Lee, Ju Cheng, Zongli Zheng, William E. Butler, Pratik Multani, Edna Chow Maneval, Sun Ha Paek, Brian D. Toyota, Dora Dias-Santagata, Sandro Santagata, Javier Romero, Alice T. Shaw, Anna F. Farago, Stephen Yip, Daniel P. Cahill, Tracy T. Batchelor, A. John Iafrate, Priscilla K. Brastianos
Publikováno v:
npj Precision Oncology, Vol 1, Iss 1, Pp 1-5 (2017)
Abstract Glioneuronal tumors constitute a histologically diverse group of primary central nervous system neoplasms that are typically slow-growing and managed conservatively. Genetic alterations associated with glioneuronal tumors include BRAF mutati
Externí odkaz:
https://doaj.org/article/566d486d09384fbf8d3ccde6c3b6828b
Autor:
Andreas Weiss, Edwige Lorthiois, Louise Barys, Kim S. Beyer, Claudio Bomio-Confaglia, Heather Burks, Xueying Chen, Xiaoming Cui, Ruben de Kanter, Lekshmi Dharmarajan, Carmine Fedele, Marc Gerspacher, Daniel Alexander Guthy, Victoria Head, Ashley Jaeger, Eloísa Jiménez Núñez, Jeffrey D. Kearns, Catherine Leblanc, Sauveur-Michel Maira, Jason Murphy, Helen Oakman, Nils Ostermann, Johannes Ottl, Pascal Rigollier, Danielle Roman, Christian Schnell, Richard Sedrani, Toshio Shimizu, Rowan Stringer, Andrea Vaupel, Hans Voshol, Peter Wessels, Toni Widmer, Rainer Wilcken, Kun Xu, Frederic Zecri, Anna F. Farago, Simona Cotesta, Saskia M. Brachmann
Publikováno v:
Cancer Discovery. 12:1500-1517
Covalent inhibitors of KRASG12C have shown antitumor activity against advanced/metastatic KRASG12C-mutated cancers, though resistance emerges and additional strategies are needed to improve outcomes. JDQ443 is a structurally unique covalent inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2edd83624df412b8b1d836bfe665fa6
https://doi.org/10.1158/2159-8290.cd-22-0158
https://doi.org/10.1158/2159-8290.cd-22-0158
Autor:
Saskia M. Brachmann, Simona Cotesta, Anna F. Farago, Frederic Zecri, Kun Xu, Rainer Wilcken, Toni Widmer, Peter Wessels, Hans Voshol, Andrea Vaupel, Rowan Stringer, Toshio Shimizu, Richard Sedrani, Christian Schnell, Danielle Roman, Pascal Rigollier, Johannes Ottl, Nils Ostermann, Helen Oakman, Jason Murphy, Sauveur-Michel Maira, Catherine Leblanc, Jeffrey D. Kearns, Eloísa Jiménez Núñez, Ashley Jaeger, Victoria Head, Daniel Alexander Guthy, Marc Gerspacher, Carmine Fedele, Lekshmi Dharmarajan, Ruben de Kanter, Xiaoming Cui, Xueying Chen, Heather Burks, Claudio Bomio-Confaglia, Kim S. Beyer, Louise Barys, Edwige Lorthiois, Andreas Weiss
Supplementary Data from Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d58af020ff3289026b12e3df1b9a0f4
https://doi.org/10.1158/2159-8290.22541471.v1
https://doi.org/10.1158/2159-8290.22541471.v1
Autor:
Saskia M. Brachmann, Simona Cotesta, Anna F. Farago, Frederic Zecri, Kun Xu, Rainer Wilcken, Toni Widmer, Peter Wessels, Hans Voshol, Andrea Vaupel, Rowan Stringer, Toshio Shimizu, Richard Sedrani, Christian Schnell, Danielle Roman, Pascal Rigollier, Johannes Ottl, Nils Ostermann, Helen Oakman, Jason Murphy, Sauveur-Michel Maira, Catherine Leblanc, Jeffrey D. Kearns, Eloísa Jiménez Núñez, Ashley Jaeger, Victoria Head, Daniel Alexander Guthy, Marc Gerspacher, Carmine Fedele, Lekshmi Dharmarajan, Ruben de Kanter, Xiaoming Cui, Xueying Chen, Heather Burks, Claudio Bomio-Confaglia, Kim S. Beyer, Louise Barys, Edwige Lorthiois, Andreas Weiss
Covalent inhibitors of KRASG12C have shown antitumor activity against advanced/metastatic KRASG12C-mutated cancers, though resistance emerges and additional strategies are needed to improve outcomes. JDQ443 is a structurally unique covalent inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::090908cffff39039ae33828ed26022f4
https://doi.org/10.1158/2159-8290.c.6549647
https://doi.org/10.1158/2159-8290.c.6549647
Autor:
Benjamin J. Drapkin, Nicholas J. Dyson, Mari Mino-Kenudson, Alice T. Shaw, Michael S. Lawrence, Daniel A. Haber, Shyamala Maheswaran, Aaron N. Hata, Lecia V. Sequist, Subba R. Digumarthy, Elizabeth A. Kennedy, Taronish D. Dubash, Marina Kem, Robert Morris, David T. Myers, Sarah Phat, David A. Barbie, Deepa Rangachari, Jun Zhong, J. Paul Marcoux, Rebecca S. Heist, Yin P. Hung, Marcello Stanzione, Beow Y. Yeap, Anna F. Farago
Small-cell lung cancer (SCLC) is an aggressive malignancy in which inhibitors of PARP have modest single-agent activity. We performed a phase I/II trial of combination olaparib tablets and temozolomide (OT) in patients with previously treated SCLC. W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::869258f3af20f270daabeb7a145a2298
https://doi.org/10.1158/2159-8290.c.6548270.v1
https://doi.org/10.1158/2159-8290.c.6548270.v1
Autor:
Aaron N. Hata, Paul E. Hughes, Cyril H. Benes, Angela Coxon, Sean P. Brown, Kristopher A. Sarosiek, Justin F. Gainor, Christopher G. Azzoli, Anna F. Farago, Zofia Piotrowska, Lecia V. Sequist, Colleen Keyes, John H. Shin, Daniel P. Cahill, Kevin A. Raskin, Cameron D. Wright, Michael Lanuti, Lorin A. Ferris, Kristof Vajda, Diamanda Rigas, Cameron Fraser, Chendi Li, Hannah L. Archibald, Maria Gomez-Caraballo, Nicole Phan, Samantha J. Bilton, Daria Timonina, Sean Caenepeel, Faria M. Siddiqui, Varuna Nangia
BH3 mimetic drugs, which inhibit prosurvival BCL2 family proteins, have limited single-agent activity in solid tumor models. The potential of BH3 mimetics for these cancers may depend on their ability to potentiate the apoptotic response to chemother
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70abe6bdd9a6b3e57487dfcfd1b546b5
https://doi.org/10.1158/2159-8290.c.6547298.v1
https://doi.org/10.1158/2159-8290.c.6547298.v1
Autor:
Filippo G. De Braud, Alice T. Shaw, Pratik S. Multani, Zachary Hornby, Edna Chow-Maneval, David Luo, Rupal Patel, Ann D. Johnson, Karey Kowalski, Jason Christiansen, Gang Li, Elena Ardini, Matteo Duca, Silvia Damian, Sara Cresta, Angelo Vanzulli, Andrea Sartore-Bianchi, Laura Palmeri, Katia Bencardino, Alessio Amatu, Michele Schirru, Giovanna Marrapese, Giulio Cerea, Laura Giannetta, Robert Doebele, Stephen V. Liu, Jennifer J. Wheler, Anna F. Farago, Todd M. Bauer, Jeeyun Lee, Myung Ju Ahn, Manish Patel, Sai-Hong Ignatius Ou, Salvatore Siena, Alexander Drilon
DOC- 25K, Supplementary Tables 1-6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd48e1f6275a397aaf95adba086a40ff
https://doi.org/10.1158/2159-8290.22531320.v1
https://doi.org/10.1158/2159-8290.22531320.v1